50 articles, transcripts, and reports
The controversy surrounding biotechnology firm Biogen’s (NASDAQ: BIIB) Alzheimer’s drug Aducanumab took a positive turn last week after the FDA issued a favorable statement on…
Biogen Inc. (NASDAQ: BIIB) Q3 2020 earnings call dated Oct. 21, 2020 Corporate Participants: Joe Mara — Head of Investor Relations Michel Vounatsos — Chief Executive Officer Alfred W. Sandrock,…
Biogen Inc. (NASDAQ: BIIB) Q2 2020 earnings call dated July 22, 2020 Corporate Participants: Joe Mara — Vice President of Finance and Head of Investor Relations Michel…
Biogen (NASDAQ: BIIB) reported a 12% increase in adjusted EPS and 2% growth in revenue for the second quarter of 2020. Adjusted EPS of $10.26…
Biogen Inc (BIIB) Q1 2020 earnings call dated Apr. 22, 2020 Corporate Participants: Joe Mara — Vice President, Investor Relations Michel Vounatsos — Chief Executive Officer Alfred Sandrock, Jr. — Executive…
Biogen Inc. (NASDAQ: BIIB) reported its financial results for the quarter ended March 31, 2020 today. Biogen posted a 1% decline in earnings for the…
Biogen Inc (BIIB) Q4 2019 earnings call dated Jan. 30, 2020 Corporate Participants: Joe Mara — Vice President, Investor Relations Michel Vounatsos — Chief Executive Officer Alfred Sandrock, Jr. — Executive…
— Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter 2019 adjusted earnings of $8.34 per share versus $8.02 per share expected. — Total revenues increased by…
Biogen Inc. (NASDAQ: BIIB) reported a 7% increase in earnings for the third quarter of 2019 as spinal muscular atrophy drug Spinraza and biosimilars drove…
The market value of pharma giant Biogen, Inc. (NASDAQ: BIIB) declined by a third in March when the stock suffered a heavy blow after the…
